Vilazodone HCL (Viibryd): A serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder

P and T

Volumn 37, Issue 1, 2012, Pages 28-31

  Cruz, Martin Paspe ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BUSPIRONE; CIMETIDINE; ERYTHROMYCIN; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRIPTAN DERIVATIVE; TRYPTOPHAN; VILAZODONE; WARFARIN;

ABNORMAL DREAMING; AGITATION; AKATHISIA; ANORGASMIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; CONFUSION; DECREASED APPETITE; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEART PALPITATION; HUMAN; HYPONATREMIA; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD CHANGE; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; ORGASM; PARESTHESIA; PATIENT MONITORING; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; RESTLESSNESS; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TREMOR; VOMITING; XEROSTOMIA;

EID: 84856039462     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62(6):617-627.
2. World Health Organization. Depression. Available at: www.who.int/mental_health/management/depression/definition/en. Accessed November 8, 2011.
3. World Health Organization. The World Health Report 2004: Statistical Annex. Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Available at: www.who.int/ whr/ 2004/annex/topic/en/annex_3_en.pdf. Accessed November 8, 2011.
4. IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion, April 1, 2010. Available at: www.imshealth.com. Accessed November 8, 2011.
5. Richelson E. Serotonin: And what about its side effects? Depress Anxiety 1998; 7(Suppl 1):18-20.
6. Blier P. Norepinephrine and selective norepinephrine reuptake inhibitors in depression and mood disorders: Their pivotal roles. J Psychiatry Neurosci 2001; 26(Suppl):S1-S2.
7. Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007;3(2):193-209.
8. Hirschfield RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options. J Clin Psychiatry 2002;63:826-837.
9. ® (vilazodone HCl) Tablets, prescribing information. St. Louis: Forest Laboratories; April 2011. Available at: www.frx.com/pi/viibryd_pi.pdf. Accessed November 8, 2011.
10. FDA approves Viibryd to treat major depressive disorder, January 21, 2011. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm240642.htm. Accessed November 8, 2011.
11. Thomson Reuters Drugdex. Vilazodone. Available at: http://thomsonreuters.com/products_services/healthcare/healthcare_products/a-z/drugdex_system. Accessed July 1, 2011.
12. Fallon Community Health Plan. Available at: www.fchp.org/ppact/Viibryd_CIA_052011.pdf. Accessed December 19, 2011.
13. restat, Issue 109, May 2011. Available at: www.restat.com/media/restat/pdf/costimpact/Viibryd_CIA_052011.pdf. Accessed December 19, 2011.